Table 2.

Plasma midazolam clearance and urinary 6β-hydroxycortisol:cortisol ratio for CYP3A phenotyping in men and women before (baseline) and after 28 days of fluvoxamine (post treatment)

Subject no.	Midazolam CL *† (ml min−1 kg−1) at baseline	Midazolam CL‡ (ml min−1 kg−1) post treatment	6β-Hydroxycortisol: cortisol ratio* at baseline	6β-Hydroxycortisol: cortisol ratio‡ post treatment
Female
Mean	8.1 ± 2.4	5.9 ± 2.7	12.6 ± 8.7	6.0 ± 4.0
CV %	29.1	45.4	69.3	67.2
Male
Mean	7.6 ± 0.9	4.7 ± 0.9	7.3 ± 2.5	4.5 ± 1.5
CV %	12.3	18.5	34.5	32.1
Overall
Mean§	7.9 ± 1.8	5.3 ± 2.0	10.0 ± 6.8	5.3 ± 3.1
CV %	22.5	38.1	68.4	58.1

Data are given as mean± SD.

^*Values were pooled of visits 1–6 for each subject.

^†Previously published by Kashuba et al. [6].

^‡Values were pooled of visits 7–8 for each subject.

^§Overall mean indicates the mean for all male and female subjects.